Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.61 |
| ▸ | MASP2 | O00187 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809131 | 0.93 | HTR2C (0.64) | F2MASP2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5900838 | 0.92 | HTR2C (0.62) | F2MASP2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5900833 | 0.92 | HTR2C (0.62) | F2MASP2HTR2CHTR2B | |
| SCHEMBL25489409 | 0.86 | HTR2C (0.54) | F2MASP2HTR2CHTR2B | |
| SCHEMBL14542806 | 0.84 | HTR2C (0.52) | F2MASP2HTR2CHTR2B | |
| SCHEMBL13238639 | 0.83 | HTR2C (0.51) | F2MASP2HTR2CHTR2B | |
| SCHEMBL19309488 | 0.82 | ALDH1A1 (0.62) | F2MASP2HTR2C | |
| Hydrochloric Acid SCHEMBL23452425 | 0.82 | HTR2C (0.50) | F2MASP2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL23452421 | 0.82 | HTR2C (0.50) | F2MASP2HTR2CHTR2B | |
| SCHEMBL13111216 | 0.80 | KDM4E (0.51) | F2MASP2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | claimed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | claimed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | claimed |
| EP-1283837-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-02-19 | — | — | EP | claimed |
| WO-2001087879-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | claimed |
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | disclosed |
| EP-1283837-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087879-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885MASP2 87/4885HTR2C 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.